Illumina Director Daniel Bradbury Sells 2,100 Shares (ILMN)
Illumina (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of Illumina stock on the open market in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $171.17, for a total transaction of $359,457.00. Following the transaction, the director now directly owns 12,466 shares of the company’s stock, valued at approximately $2,133,805. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Illumina (NASDAQ:ILMN) traded down 0.67% during mid-day trading on Monday, hitting $169.38. 1,485,606 shares of the company’s stock traded hands. Illumina has a one year low of $67.50 and a one year high of $183.30. The stock has a 50-day moving average of $152. and a 200-day moving average of $141.6. The company has a market cap of $21.748 billion and a P/E ratio of 119.92.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.46 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.45 by $0.01. The company had revenue of $421.00 million for the quarter, compared to the consensus estimate of $391.50 million. During the same quarter in the prior year, the company posted $0.46 earnings per share. The company’s quarterly revenue was up 27.2% on a year-over-year basis. Analysts expect that Illumina will post $2.16 EPS for the current fiscal year.
A number of research firms have recently commented on ILMN. Analysts at Ned Davis Research upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Separately, analysts at Maxim Group upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $205.00 price target on the stock. Finally, analysts at Bank of America reiterated a “buy” rating on shares of Illumina in a research note on Wednesday, April 23rd. They now have a $195.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Illumina presently has an average rating of “Buy” and a consensus target price of $144.34.
Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.